Silence Therapeutics PLC
SLN
Detailliertes Diagramm anzeigen
5.030USD
+0.020+0.40%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
712.76MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+0.40%
5 Tage
+3.07%
1 Monat
-8.88%
6 Monate
+32.37%
Seit Jahresbeginn
-26.89%
1 Jahr
-72.45%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert：2025-09-18Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer guten Aktienmarktperformance und starker technischer Indikatoren unterstützen die Fundamentaldaten den aktuellen Trend nicht. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
7
Analysten
Kaufen
Aktuelles Rating
30.667
Kursziel
+512.11%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=99.76%)
performance_growth_period
performance_growth_period_desc%!(EXTRA string=43.26M)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-8.92)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=33.68M, string=29.62%)
institutional_hold%!(EXTRA string=Invesco)
institutional_hold_desc%!(EXTRA string=Invesco, string=1.69K)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
BörsenkürzelSLN
UnternehmenSilence Therapeutics PLC
CEOMr. Craig A. Tooman
Websitehttps://www.silence-therapeutics.com/
Verwandte Finanzinstrumente
-0.35%
-4.12%
+3.22%
+1.88%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+2.93%
+0.93%
+5.59%
+3.22%
0.00%
+2.85%
